1. Home
  2. CEPU vs PHVS Comparison

CEPU vs PHVS Comparison

Compare CEPU & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Puerto S.A. (each represents ten)

CEPU

Central Puerto S.A. (each represents ten)

HOLD

Current Price

$14.33

Market Cap

2.1B

Sector

Utilities

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$34.95

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CEPU
PHVS
Founded
1989
2015
Country
Argentina
Switzerland
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.4B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
CEPU
PHVS
Price
$14.33
$34.95
Analyst Decision
Strong Buy
Buy
Analyst Count
1
11
Target Price
$17.50
$41.82
AVG Volume (30 Days)
250.3K
566.0K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.24
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.43
$19.12
52 Week High
$18.50
$36.60

Technical Indicators

Market Signals
Indicator
CEPU
PHVS
Relative Strength Index (RSI) 43.38 57.18
Support Level $13.87 $24.73
Resistance Level $16.45 $36.60
Average True Range (ATR) 0.57 1.64
MACD -0.04 -0.14
Stochastic Oscillator 20.42 54.17

Price Performance

Historical Comparison
CEPU
PHVS

About CEPU Central Puerto S.A. (each represents ten)

Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity. The company derives maximum revenue from Electric Power Generation from conventional sources segment.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: